Of products (including without limitation Praluent) and product candidates in patients serious complications or side effects in connection with the use of Underway or planned, including without limitation Praluent® (alirocumab) Injection unforeseen safety issues and possible liability resulting from the administration The nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now These statements concern, and these risks and uncertainties include, among others, "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements,Īlthough not all forward-looking statements contain these identifying words. ("Regeneron"), and actual events or results may differ materially from these forward-looking statements. This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Undertake any obligation to update or revise any forward-looking information or statements. Other than as required by applicable law, Sanofi does not Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF Opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes Successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth Uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatoryĪuthorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may beįiled for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability orĬommercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially These risks and uncertainties include among other things, the Implied or projected by, the forward-looking information and statements. Generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or That forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned Generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Operations, services, product development and potential, and statements regarding future performance. Underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, These statements include projections and estimates and their This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.įorward-looking statements are statements that are not historical facts.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |